HISTORY: Heart and Ischemic STrOke Relationship studY

Sponsor
University Hospital Olomouc (Other)
Overall Status
Unknown status
CT.gov ID
NCT01541163
Collaborator
Ministry of Health, Czech Republic (Other), Palacky University (Other)
500
1
98
5.1

Study Details

Study Description

Brief Summary

Although cardio-embolic etiology of ischemic stroke (IS) is largely respected, there is still no clear recommendation for routine complex cardiological examination in all IS patients.

Using complex cardiological examination the investigators expect:
  1. more accurate detection of patients with concomitant heart disease (cardiac rhythm disorder, valve disorders, acute coronary syndrome, cardiac thrombus and myxoma, atrial and ventricle septum defects)

  2. higher number of etiologically determinated IS, which is crucial for accurate secondary prevention.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The investigators expect significant changes of biochemical parameters (NT pro B-type of natriuretic peptide, pro-atrial natriuretic peptide, creatinkinase MB, troponin T), inflammatory markers (interleukine 6, procalcitonin, high sensitive C-reactive protein), and coagulation parameters in patients with CE IS compared to other causes of IS.

    Assessing the glomerular filtration of cystatin C, glycated haemoglobin and serum lipids and its correlation with prior medicament use will allow to evaluate the long-term compensation of arterial hypertension, diabetes mellitus and dyslipidemia in IS patients.

    In addition to the above mentioned comprehensive cardiological examinations, 1- and 3-week ECG-Holter will be performed in subpopulation of patients old up to 50 years and with cryptogenic ischemic stroke in the period from 1st May 2013 to 31st December 2015. These patients will also fill in a special epidemiologic questionnaire. Anticipated enrollment in this substudy of HISTORY study is 40 - 80 patients.

    In selected young cryptogenic stroke patients, a subcutaneous cardiac monitor was implanted for the detection of paroxysmal atrial fibrillation in the period from 1st January 2014 to 31st December 2015.

    From 2016 in young ischemic stroke (IS) patients under 50 years, a standard perfusion/ventilation scintigraphy of lungs will be performed to exclude acute pulmonary embolization (coincidental) in case of elevated serum D-dimers after admission.

    In all enrolled young IS patients, a BP Holter will be performed after the discharge home to exclude possible arterial hypertension, which did not presented during hospitalization.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Assessment of Relationship Between Acute Ischemic Stroke and Heart Disease
    Study Start Date :
    Sep 1, 2010
    Anticipated Primary Completion Date :
    Jun 1, 2018
    Anticipated Study Completion Date :
    Nov 1, 2018

    Arms and Interventions

    Arm Intervention/Treatment
    Acute Ischemic Stroke

    Patients with acute ischemic stroke admitted within 12 hours after onset.

    Outcome Measures

    Primary Outcome Measures

    1. To assess the serum level profile of cardiac troponin T (cTnT) in acute ischemic stroke (AIS) patients and to evaluate factors associated with increased serum level of cTnT. [Within 12 hours after ischemic stroke onset.]

    Secondary Outcome Measures

    1. Correlation between location and volume of brain infarction. [At admission within 12 hours after stroke onset and after 24hours.]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Ischemic stroke admitted within 12 hours from stroke onset at stroke center
    Exclusion Criteria:
    • none

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University Hospital Olomouc Olomouc Czechia 775 20

    Sponsors and Collaborators

    • University Hospital Olomouc
    • Ministry of Health, Czech Republic
    • Palacky University

    Investigators

    • Study Director: Michal Kral, MD, University Hospital Olomouc

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Michal Kral, Study Director, University Hospital Olomouc
    ClinicalTrials.gov Identifier:
    NCT01541163
    Other Study ID Numbers:
    • NT 11046-6/2010
    • Grant project No.86-17
    First Posted:
    Feb 29, 2012
    Last Update Posted:
    Nov 1, 2017
    Last Verified:
    Oct 1, 2017
    Keywords provided by Michal Kral, Study Director, University Hospital Olomouc
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 1, 2017